Hydrocodone and oxycodone do not test the same. On a standard drug test, they are treated as separate substances with their own screening categories, their own cutoff levels, and their own confirmation targets. A lab that properly tests for both will be able to tell exactly which one you took. However, the type of test matters enormously, because many common screening panels can miss one or both of these drugs entirely.
Why Standard Drug Screens Often Miss Both
The most common clinical drug screens, including the typical 5-panel and 10-panel tests used by many employers and hospitals, rely on immunoassays designed to detect morphine. These tests work by using antibodies that bind to morphine and its close relatives, like codeine and heroin (which the body converts to morphine). Hydrocodone and oxycodone are structurally different enough from morphine that these antibodies don’t reliably pick them up.
Oxycodone is especially likely to slip through. Because of the structural gap between oxycodone and morphine, some commercial opiate immunoassays require a concentration more than six times higher than morphine to trigger a positive result. One widely used assay (Roche OnLine) showed essentially no detection of oxycodone even at concentrations 50 times higher than morphine. Hydrocodone fares somewhat better on certain platforms. The Syva EMIT assay, for example, detects hydrocodone at nearly the same sensitivity as morphine, but other assays need two to three times the concentration to flag it.
The practical takeaway: a basic opiate screen can easily return a negative result for someone actively taking either drug. Separate immunoassays designed specifically for oxycodone and hydrocodone are needed for reliable detection, and many standard panels simply don’t include them.
Federal Testing Treats Them as Distinct Categories
Federal workplace drug testing, regulated by the Department of Health and Human Services, does screen for both drugs but places them in entirely separate categories with different cutoff thresholds.
For urine testing, hydrocodone and its metabolite hydromorphone are screened together at a cutoff of 300 ng/mL. Oxycodone and its metabolite oxymorphone have a lower screening cutoff of 100 ng/mL, making that category more sensitive. If the initial screen comes back positive, confirmatory testing looks for each specific drug at 100 ng/mL for both categories.
Oral fluid testing follows the same split. Both categories use a 30 ng/mL screening cutoff and a 15 ng/mL confirmation cutoff, but they remain separate line items. A positive result in one category says nothing about the other. If you’re taking hydrocodone, it won’t show up in the oxycodone category, and vice versa.
How Confirmatory Testing Tells Them Apart
When an initial screen comes back positive or when precise identification matters (pain management clinics, legal cases, federal employment), labs use a technique called liquid chromatography-tandem mass spectrometry. This method identifies and measures individual molecules by their exact chemical signature, making it virtually impossible to confuse hydrocodone with oxycodone. It can quantify both drugs across a wide range, from 50 ng/mL to over 100,000 ng/mL.
There is one wrinkle. In patients taking high doses of oxycodone, tiny amounts of hydrocodone can appear in urine as a minor metabolic byproduct, not from taking hydrocodone but as a trace conversion in the body. Labs that work with pain patients account for this. The general rule is that when oxycodone levels exceed 100,000 ng/mL, hydrocodone should still be below 1,500 ng/mL. At lower oxycodone levels, hydrocodone should stay under 500 ng/mL. Anything above those thresholds suggests the person actually took hydrocodone separately.
Different Metabolites, Different Fingerprints
Your body breaks down hydrocodone and oxycodone through different pathways, producing different metabolites that serve as chemical fingerprints on a drug test.
Hydrocodone is converted primarily into hydromorphone, an active and potent metabolite. This is why federal testing screens for hydrocodone and hydromorphone together. If you’re prescribed hydrocodone, expect both the parent drug and hydromorphone to appear on a detailed test.
Oxycodone follows a different route. The liver’s primary enzyme converts most of it into noroxycodone, a weaker compound. A smaller portion becomes oxymorphone. Federal testing screens for oxycodone and oxymorphone as a pair. The effects of oxycodone come almost entirely from the parent drug itself rather than from these metabolites, but both can show up in your sample.
These distinct metabolic profiles mean that even if a screening test were somehow ambiguous, confirmatory testing can identify exactly which drug was taken based on which metabolites are present.
Detection Windows Are Similar
Both drugs follow roughly the same timeline in urine. Concentrations peak within about 8 hours of taking a dose, and in studies using immunoassay testing at a 300 ng/mL cutoff, both hydrocodone and oxycodone were detectable for 6 to 24 hours. Concentrations generally drop below 300 ng/mL within 24 to 48 hours.
These windows can shift depending on the dose, how long you’ve been taking the medication, your metabolism, kidney function, and whether you’re taking an extended-release formulation. But for a single standard dose, the one-to-two-day window applies to both drugs.
What Can Cause a False Positive
False positives on opiate immunoassays are possible but come from sources unrelated to hydrocodone or oxycodone. Poppy seeds contain trace amounts of morphine and codeine and can trigger a positive on a morphine-based screen. Certain medications, including some antibiotics (ciprofloxacin and other quinolones), the tuberculosis drug rifampin, the blood pressure medication verapamil, the antipsychotic quetiapine, and diphenhydramine (the active ingredient in Benadryl), have all been associated with false-positive opiate screens.
These false positives affect the general opiate category, not the oxycodone-specific or hydrocodone-specific assays. And any positive screening result should be confirmed with mass spectrometry, which eliminates false positives by identifying the exact molecules present.
What This Means for Your Situation
If you’re taking one of these medications with a valid prescription and facing a drug test, the key question is what kind of test is being used. A basic 5-panel or 10-panel screen may not detect either drug at all, since it typically only looks for morphine and its close relatives. An expanded panel or federal-standard test will detect both but will clearly distinguish between them. They show up in separate categories with separate confirmation targets.
If you’re concerned about how a prescribed medication will appear on a test, disclosing your prescription to the medical review officer (the physician who interprets workplace drug test results) is the standard process. A confirmed positive for a drug you’re legitimately prescribed is reported differently than an unexplained positive.